Kite Pharma, Inc. (NASDAQ:KITE) – Analysts at SunTrust Banks issued their Q1 2018 earnings per share (EPS) estimates for shares of Kite Pharma in a research note issued on Tuesday. SunTrust Banks analyst P. Lawson expects that the biopharmaceutical company will post earnings per share of ($2.26) for the quarter. SunTrust Banks also issued estimates for Kite Pharma’s Q2 2018 earnings at ($2.26) EPS, Q3 2018 earnings at ($2.21) EPS, Q4 2018 earnings at ($1.96) EPS and FY2020 earnings at $0.99 EPS.

KITE has been the subject of several other research reports. FBR & Co reissued an “outperform” rating and set a $91.00 price objective (up previously from $90.00) on shares of Kite Pharma in a report on Tuesday, May 9th. Canaccord Genuity set a $115.00 price objective on Kite Pharma and gave the stock a “buy” rating in a report on Tuesday, June 27th. Roth Capital reissued a “buy” rating and set a $93.00 price objective on shares of Kite Pharma in a report on Tuesday, July 4th. Jefferies Group LLC boosted their price objective on Kite Pharma from $101.00 to $121.00 and gave the stock a “buy” rating in a report on Monday, July 10th. Finally, Cowen and Company reissued an “outperform” rating on shares of Kite Pharma in a report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $87.66.

ILLEGAL ACTIVITY NOTICE: This article was published by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/09/kite-pharma-inc-nasdaqkite-expected-to-earn-q1-2018-earnings-of-2-26-per-share.html.

Kite Pharma (KITE) traded down 0.13% on Wednesday, hitting $119.97. 537,086 shares of the stock were exchanged. The company has a 50-day moving average price of $103.84 and a 200-day moving average price of $79.27. Kite Pharma has a 52-week low of $39.82 and a 52-week high of $120.78. The firm’s market cap is $6.78 billion.

Kite Pharma (NASDAQ:KITE) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.03. The firm had revenue of $10.10 million during the quarter, compared to analysts’ expectations of $9.59 million. Kite Pharma had a negative net margin of 1,166.54% and a negative return on equity of 55.80%. The business’s revenue for the quarter was up 110.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.91) earnings per share.

A number of hedge funds have recently made changes to their positions in KITE. Principal Financial Group Inc. increased its stake in shares of Kite Pharma by 637.7% in the second quarter. Principal Financial Group Inc. now owns 53,730 shares of the biopharmaceutical company’s stock valued at $5,570,000 after buying an additional 46,447 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Kite Pharma by 22.7% in the second quarter. Pacer Advisors Inc. now owns 5,851 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 1,083 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of Kite Pharma by 26.3% in the second quarter. Prudential Financial Inc. now owns 5,000 shares of the biopharmaceutical company’s stock valued at $518,000 after buying an additional 1,040 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Kite Pharma by 9.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 24,127 shares of the biopharmaceutical company’s stock valued at $2,501,000 after buying an additional 2,164 shares during the last quarter. Finally, Turner Investments LLC increased its stake in shares of Kite Pharma by 113.3% in the second quarter. Turner Investments LLC now owns 6,400 shares of the biopharmaceutical company’s stock valued at $663,000 after buying an additional 3,400 shares during the last quarter. Hedge funds and other institutional investors own 84.96% of the company’s stock.

In other Kite Pharma news, COO Cynthia M. Butitta sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $88.55, for a total value of $885,500.00. Following the completion of the sale, the chief operating officer now owns 127,795 shares in the company, valued at $11,316,247.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Cynthia M. Butitta sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $100.81, for a total value of $504,050.00. Following the completion of the sale, the chief operating officer now owns 114,845 shares of the company’s stock, valued at approximately $11,577,524.45. The disclosure for this sale can be found here. Insiders sold 165,099 shares of company stock valued at $16,244,448 in the last quarter. Corporate insiders own 14.00% of the company’s stock.

Kite Pharma Company Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Earnings History and Estimates for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.